Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustain...
Ausführliche Beschreibung
Autor*in: |
Olshansky, Brian [verfasserIn] Kail, John [verfasserIn] Kopp, Douglas [verfasserIn] Wilber, David [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
1993 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Clinical drug investigation - Berlin [u.a.] : Springer, 1989, 6(1993), 3 vom: Sept., Seite 119-126 |
---|---|
Übergeordnetes Werk: |
volume:6 ; year:1993 ; number:3 ; month:09 ; pages:119-126 |
Links: |
---|
DOI / URN: |
10.1007/BF03259731 |
---|
Katalog-ID: |
SPR032998953 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR032998953 | ||
003 | DE-627 | ||
005 | 20230519200755.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s1993 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/BF03259731 |2 doi | |
035 | |a (DE-627)SPR032998953 | ||
035 | |a (SPR)BF03259731-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Olshansky, Brian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia |
264 | 1 | |c 1993 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. | ||
650 | 4 | |a Ventricular Tachycardia |7 (dpeaa)DE-He213 | |
650 | 4 | |a Antiarrhythmic Drug |7 (dpeaa)DE-He213 | |
650 | 4 | |a Flecainide |7 (dpeaa)DE-He213 | |
650 | 4 | |a Encainide |7 (dpeaa)DE-He213 | |
650 | 4 | |a Sustained Ventricular Tachycardia |7 (dpeaa)DE-He213 | |
700 | 1 | |a Kail, John |e verfasserin |4 aut | |
700 | 1 | |a Kopp, Douglas |e verfasserin |4 aut | |
700 | 1 | |a Wilber, David |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical drug investigation |d Berlin [u.a.] : Springer, 1989 |g 6(1993), 3 vom: Sept., Seite 119-126 |w (DE-627)327645083 |w (DE-600)2043793-6 |x 1179-1918 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:1993 |g number:3 |g month:09 |g pages:119-126 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03259731 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2190 | ||
936 | b | k | |a 44.40 |q ASE |
951 | |a AR | ||
952 | |d 6 |j 1993 |e 3 |c 09 |h 119-126 |
author_variant |
b o bo j k jk d k dk d w dw |
---|---|
matchkey_str |
article:11791918:1993----::fiaynavrefetomrcznfret |
hierarchy_sort_str |
1993 |
bklnumber |
44.40 |
publishDate |
1993 |
allfields |
10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126 |
spelling |
10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126 |
allfields_unstemmed |
10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126 |
allfieldsGer |
10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126 |
allfieldsSound |
10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126 |
language |
English |
source |
Enthalten in Clinical drug investigation 6(1993), 3 vom: Sept., Seite 119-126 volume:6 year:1993 number:3 month:09 pages:119-126 |
sourceStr |
Enthalten in Clinical drug investigation 6(1993), 3 vom: Sept., Seite 119-126 volume:6 year:1993 number:3 month:09 pages:119-126 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Ventricular Tachycardia Antiarrhythmic Drug Flecainide Encainide Sustained Ventricular Tachycardia |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Clinical drug investigation |
authorswithroles_txt_mv |
Olshansky, Brian @@aut@@ Kail, John @@aut@@ Kopp, Douglas @@aut@@ Wilber, David @@aut@@ |
publishDateDaySort_date |
1993-09-01T00:00:00Z |
hierarchy_top_id |
327645083 |
dewey-sort |
3610 |
id |
SPR032998953 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032998953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200755.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259731</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032998953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259731-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Olshansky, Brian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiarrhythmic Drug</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Flecainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Encainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sustained Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kail, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopp, Douglas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilber, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">6(1993), 3 vom: Sept., Seite 119-126</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:119-126</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259731</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1993</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">119-126</subfield></datafield></record></collection>
|
author |
Olshansky, Brian |
spellingShingle |
Olshansky, Brian ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia |
authorStr |
Olshansky, Brian |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)327645083 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1179-1918 |
topic_title |
610 ASE 44.40 bkl Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 |
topic |
ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia |
topic_unstemmed |
ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia |
topic_browse |
ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Clinical drug investigation |
hierarchy_parent_id |
327645083 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Clinical drug investigation |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)327645083 (DE-600)2043793-6 |
title |
Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia |
ctrlnum |
(DE-627)SPR032998953 (SPR)BF03259731-e |
title_full |
Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia |
author_sort |
Olshansky, Brian |
journal |
Clinical drug investigation |
journalStr |
Clinical drug investigation |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
1993 |
contenttype_str_mv |
txt |
container_start_page |
119 |
author_browse |
Olshansky, Brian Kail, John Kopp, Douglas Wilber, David |
container_volume |
6 |
class |
610 ASE 44.40 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Olshansky, Brian |
doi_str_mv |
10.1007/BF03259731 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
efficacy and adverse effects of moracizine for ventricular tachycardia |
title_auth |
Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia |
abstract |
Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. |
abstractGer |
Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. |
abstract_unstemmed |
Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
container_issue |
3 |
title_short |
Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia |
url |
https://dx.doi.org/10.1007/BF03259731 |
remote_bool |
true |
author2 |
Kail, John Kopp, Douglas Wilber, David |
author2Str |
Kail, John Kopp, Douglas Wilber, David |
ppnlink |
327645083 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/BF03259731 |
up_date |
2024-07-03T15:57:29.028Z |
_version_ |
1803574049804124160 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032998953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200755.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259731</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032998953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259731-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Olshansky, Brian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiarrhythmic Drug</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Flecainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Encainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sustained Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kail, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopp, Douglas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilber, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">6(1993), 3 vom: Sept., Seite 119-126</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:119-126</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259731</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1993</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">119-126</subfield></datafield></record></collection>
|
score |
7.399766 |